Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

15.2K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
15.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Cancer Therapies02:49

Cancer Therapies

8.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K
Phase II Reactions: Miscellaneous Conjugation Reactions01:19

Phase II Reactions: Miscellaneous Conjugation Reactions

135
Phase II biotransformations are detoxification mechanisms that conjugate xenobiotics with endogenous substances, neutralizing their toxicity.
A key example involves the conjugation of cyanide ions, which impair cellular respiration and alter hemoglobin into non-oxygen-carrying cyanmethemoglobin. To neutralize this threat, a sulfur atom from thiosulphate is transferred to the cyanide ion, catalyzed by the enzyme rhodanese, resulting in an inactive compound called thiocyanate. The production of...
135
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

5.0K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K
Structural Isomerism02:34

Structural Isomerism

19.8K
Isomerism in Complexes
Isomers are different chemical species that have the same chemical formula. Structural isomerism of coordination compounds can be divided into two subcategories, the linkage isomers and coordination-sphere isomers.
Linkage isomers occur when the coordination compound contains a ligand that can bind to the transition metal center through two different atoms. For example, the CN− ligand can bind through the carbon atom or through the nitrogen atom. Similarly, SCN− can...
19.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Halogenated Vitamin B<sub>6</sub>‑Attached Co(III) Photosensitizers on Polypyridyl Scaffold for Light-Induced Antibacterial Activities.

ACS omega·2026
Same author

Real-World Outcomes With Low-Dose Dasatinib (50 mg) in Imatinib-Resistant Chronic Myeloid Leukemia in Chronic Phase: A Retrospective Analysis of Efficacy and Safety.

Cancer reports (Hoboken, N.J.)·2026
Same author

Predictors of Response to Imatinib Therapy and Long-Term Outcomes in Paediatric and Adolescent Patients With Chronic Myeloid Leukaemia.

Cancer reports (Hoboken, N.J.)·2026
Same author

Novel Ru(II)-photo-antibiotics for the development of infection-resistant mask coatings.

Chemical communications (Cambridge, England)·2025
Same author

Turning the Spotlight Away from PDT: Chemodynamic Dominance of 2-(2-Bromopyridin-4-yl)-1<i>H</i>-imidazo[4,5-<i>f</i>][1,10]phenanthroline Based Ru(II)/Ir(III)/Re(I) Complexes against MDA-MB-231.

Journal of medicinal chemistry·2025
Same author

Dual functioning Ru(II)/Ir(III) complexes for ferroptosis and apoptosis in triple-negative breast cancer: a proof of concept by glutathione depletion.

Dalton transactions (Cambridge, England : 2003)·2025
Same journal

A one-step immunoassay of Tau protein based on flow cytometric counting of target-induced nanoaggregates.

Chemical communications (Cambridge, England)·2026
Same journal

Decarboxylative alkylation of unactivated olefins <i>via</i> photoinduced Fe-LMCT: access to alkylated dihydropyrazoles/tetrahydropyridazines.

Chemical communications (Cambridge, England)·2026
Same journal

MOF-ionic liquid engineered polymer electrolyte for advanced solid-state sodium metal batteries.

Chemical communications (Cambridge, England)·2026
Same journal

Chemically-fueled transient peptide hydrogel enabling programmable time-gated functions.

Chemical communications (Cambridge, England)·2026
Same journal

The first structurally characterized coordination compounds with homocysteine.

Chemical communications (Cambridge, England)·2026
Same journal

Bimetallic Bi-In interfaces on micropyramidal silicon for efficient solar-driven CO<sub>2</sub>-to-formate conversion.

Chemical communications (Cambridge, England)·2026
See all related articles

Related Experiment Video

Updated: Sep 28, 2025

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay
11:14

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay

Published on: November 10, 2013

58.0K

Os(II) complexes for catalytic anticancer therapy: recent update.

Rajesh Kushwaha1, Ashish Kumar1, Souvik Saha1

  • 1Department of Chemistry, Indian Institute of Technology (BHU), Varanasi, UP-221005, India. samya.chy@itbhu.ac.in.

Chemical Communications (Cambridge, England)
|March 29, 2022
PubMed
Summary
This summary is machine-generated.

New catalytic anticancer agents, specifically osmium (II) complexes, offer a promising alternative to platinum-based drugs by disrupting cancer cell metabolism and generating oxidative stress. These novel metallodrugs show potential for next-generation cancer therapies.

More Related Videos

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
07:20

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

14.1K
Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
05:17

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

1.7K

Related Experiment Videos

Last Updated: Sep 28, 2025

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay
11:14

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay

Published on: November 10, 2013

58.0K
Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
07:20

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

14.1K
Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
05:17

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

1.7K

Area of Science:

  • Medicinal Chemistry
  • Nanotechnology
  • Oncology

Background:

  • Rising cancer mortality and limitations of platinum-based chemotherapy necessitate novel therapeutic strategies.
  • Catalytic anticancer agents, particularly metallodrugs, are emerging as a promising alternative to traditional chemotherapeutics.
  • Metal complexes can catalyze crucial intracellular transformations, offering new avenues for cancer treatment.

Purpose of the Study:

  • To critically review the catalytic anticancer activity of osmium (II) complexes.
  • To explore the potential of these complexes as next-generation anticancer drugs.
  • To highlight their unique mechanisms of action in cancer cells.

Main Methods:

  • Review of existing literature on osmium (II) complexes as anticancer agents.
  • Analysis of their catalytic mechanisms, including transfer hydrogenation and reactive oxygen species (ROS) generation.
  • Evaluation of their potential to disrupt cancer cell metabolism.

Main Results:

  • Osmium (II) complexes demonstrate potent catalytic anticancer activities.
  • These catalysts induce in-cell catalytic transfer hydrogenation of pyruvate and quinones, leading to metabolic disorders.
  • They also facilitate photocatalytic ROS generation, inducing oxidative stress in cancer cells.

Conclusions:

  • Osmium (II) complexes represent a novel class of catalytic anticancer agents with unique mechanisms.
  • Their ability to disrupt cancer cell metabolism and induce oxidative stress makes them promising candidates for new cancer therapies.
  • Further development of these osmium (II) catalysts could lead to effective next-generation anticancer drugs.